Diabetics to benefit under latest FDA biosimilar guidance
13-05-2019
FDA releases plan to boost biosimilars development
13-12-2018
08-03-2019
jarretera / Shutterstock.com
The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Food and Drug Administration, Scott Gottlieb, biosimilars, naming convention, names, suffix, pharmacovigilance, competition, transition